Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334200 | 1.00 | LPL (0.34) | LPLLIPGIRAK4KDM5ATLR8 | |
| SCHEMBL25958846 | 1.00 | LPL (0.34) | LPLLIPGIRAK4KDM5ATLR8 | |
| SCHEMBL29081357 | 0.93 | TLR8 (0.36) | LPLLIPGIRAK4TLR8IDO1 | |
| SCHEMBL25319208 | 0.91 | TLR8 (0.35) | LPLLIPGIRAK4KDM5ATLR8 | |
| SCHEMBL25321106 | 0.91 | TLR8 (0.35) | LPLLIPGIRAK4KDM5ATLR8 | |
| SCHEMBL22041263 | 0.87 | LPL (0.39) | LPLLIPGIRAK4TLR8IDO1 | |
| SCHEMBL25322662 | 0.86 | IRAK4 (0.32) | LPLLIPGIRAK4 | |
| SCHEMBL25322665 | 0.86 | IRAK4 (0.32) | LPLLIPGIRAK4 | |
| SCHEMBL25336220 | 0.85 | IRAK4 (0.33) | LPLLIPGIRAK4IDO1TDO2 | |
| SCHEMBL25335427 | 0.85 | IRAK4 (0.33) | LPLLIPGIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | LPL 2617/4885LIPG 3322/4885IRAK4 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.